The FBI will assist Poland’s Central Anticorruption Office (CBA) in the case of UK pharmaceuticals company GlaxoSmithKline, which is suspected of bribing Polish doctors, the Polish business daily Puls Biznesu wrote April 16.
“The GKS corruption case, which has been under investigation by the CBA and Lodz prosecutor’s office since 2012 and currently includes 13 suspects, will receive assistance from the FBI,” said Pawel Wojtunik, head of the CBA.
US regulations oblige the Securities and Exchange Commission (SEC) to initiate proceedings when suspicions of corruption arise at companies listed on US stock exchanges. This may play an important role as the case develops, especially if GSK were found to have breached the Foreign and Corrupt Practices Act (FCPA).
As reported by CEE Inisght, GSK sales reps had offered bribes to doctors from Lodz in return for prescriptions for GSK drugs between 2010 and 2012.